Read our VASCERN Monthly Newsletter, your go-to source for the latest updates and developments in VASCERN. We are thrilled to have you as part of our community, and this newsletter is our way of keeping you informed, engaged, and empowered.
In the News
Discover Our New Heritable Thoracic Aortic Diseases E-Learning Course
Read more
 
Reflecting on VASCERN Days 2023: Two days of collaboration & knowledge exchange
Read more
 
MOOC From Lab to Clinic: Translational Research for Rare Diseases
Read more
 
The Rare disease community unites in an open letter for continued support of European Reference Networks
Read more
 
Apply for the 1st Edition of the VASCERN Summer School on Rare Vascular Diseases!
Read more
 
VASCERN Spotlights: Eva Collado González
Read more
 
Together4RD’s Position Statement on collaboration between ERNs and industry
Read more
 
Vascular Anomalies Working Group (VASCA-WG) CPMS Case Discussion
Read more
 
Patient-Centered HTAD Quality Measures Now Online!
Read more
 
Events
2 November 2023
VASCERN MSA-WG Monthly Meeting
Find out more
7 November 2023
VASCERN NEUROVASC-WG Monthly Meeting
Find out more
14 November 2023
VASCERN ePAG Monthly Meeting
Find out more
15 November 2023
VASCERN VASCA-WG Monthly Meeting
Find out more
20 November 2023
VASCERN PPL-WG Monthly Meeting
Find out more
Research
Establishing novel approaches to improve clinical trials for rare and ultra-rare diseases
Establishing novel approaches to improve clinical trials for rare and ultra-rare diseases
A new two-stage call for proposals titled “Establishing novel approaches to improve clinical trials for rare and ultra-rare diseases” was released on July 27, 2023, under the Horizon Europe Framework Programme (HORIZON). This project’s primary goal is to drive innovation and streamline the drug development process for rare diseases characterized by significant unmet medical needs. The application deadline for this opportunity is November 8, 2023, at 17:00 local Brussels time.
Read more
A case report of sirolimus use in early fetal management of lymphatic malformation
A case report of sirolimus use in early fetal management of lymphatic malformation
Sirolimus, by targeting the mammalian target of rapamycin (mTOR) pathway, has demonstrated efficacy on lymphatic malformations (LMs) in adults and neonates. The current hypothesis is that the earlier the lesion is treated, the better it responds. This has prompted the idea that sirolimus administration might be efficacious to treat fetal LMs as well.
Read more
facebook  twitter  linkedin  youtube